GlassScriptPhysician profile
Salman Ahmed
NPI 1952357840
$3,983.02
in general payments reported to CMS, 2019-2025
26 companies · $710 in 2025
The $710 reported for 2025 was more than what 96% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $262 · 2020: $369 · 2021: $692 · 2022: $659 · 2023: $778 · 2024: $512 · 2025: $710.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,000.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,999.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $833.76 | 2021-2025 | Azstarys |
| Glaxosmithkline, LLC. | $523.50 | 2019-2025 | Bexsero, Rotarix, Penmenvy |
| Neos Therapeutics, LP | $447.19 | 2021-2025 | Cotempla Xr-Odt, Adzenys Xr-Odt |
| Tris Pharma INC | $392.94 | 2019-2025 | Onyda Xr, Dyanavel Xr |
| Supernus Pharmaceuticals, INC. | $207.22 | 2021-2025 | Qelbree |
| Verrica Pharmaceuticals INC. | $165.81 | 2024-2025 | Ycanth |
| Pfizer INC. | $162.26 | 2019-2025 | |
| Collegium Pharmaceutical, INC. | $150.93 | 2025 | Jornay Pm |
| Takeda Pharmaceuticals U.S.A., INC. | $139.30 | 2020-2025 | Cuvitru |
| Merck Sharp & Dohme LLC | $126.02 | 2021-2025 | Gardasil 9, Vaxneuvance, Rotateq |
| Adlon Therapeutics L.P. | $113.49 | 2019-2021 | |
| Kaleo, INC. | $95.02 | 2019-2022 | |
| Cranial Technologies, INC | $89.59 | 2019-2023 | Doc Band |
| Depuy Synthes Sales INC. | $83.31 | 2024 | Trumatch, Cementralizer, Na |
| Sanofi Pasteur INC. | $75.17 | 2019-2023 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alk-Abello, INC | $71.10 | 2024-2025 | Grastek, Odactra, Neffy |
| Ironshore Pharmaceuticals INC. | $67.96 | 2020-2023 | Jornay Pm |
| Noven Therapeutics, LLC | $45.75 | 2024-2025 | Xelstrym, Secuado |
| Nestle Healthcare Nutrition INC. | $40.11 | 2021-2023 | |
| Aytu Biopharma, INC. | $31.74 | 2024 | Karbinal |
| Abbvie INC. | $24.53 | 2021 | |
| Acadia Pharmaceuticals INC | $23.01 | 2023 | Daybue |
| Novo Nordisk INC | $21.30 | 2024 | Wegovy |
| Genentech USA, INC. | $21.30 | 2019 | |
| Phadia US INC. | $16.20 | 2019 | |
| Photonicare INC | $14.51 | 2023 | Otosight Middle Ear Scope |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Salman Ahmed listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.